Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact by Oh, D. et al.
Evaluation of oseltamivir prophylaxis regimens for
reducing influenza virus infection, transmission and disease
severity in a ferret model of household contact
Ding Yuan Oh1, Sue Lowther2, James M. McCaw3,4, Sheena G. Sullivan1, Sook-Kwan Leang1, Jessica Haining2,
Rachel Arkinstall2, Anne Kelso1, Jodie Mcvernon3,4, Ian G. Barr1,5, Deborah Middleton2 and Aeron C. Hurt1,5*
1WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia; 2Australian Animal Health
Laboratory, Geelong, Victoria, Australia; 3Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute, Royal
Childrens Hospital, Parkville, Victoria, Australia; 4Melbourne School of Population and Global Health, The University of Melbourne,
Melbourne, Victoria, Australia; 5School of Applied Sciences and Engineering, Monash University, Churchill, Victoria, Australia
*Corresponding author. Tel: +61-3-93423914; Fax: +61-3-93423939; E-mail: aeron.hurt@influenzacentre.org
Received 14 January 2014; returned 25 February 2014; revised 31 March 2014; accepted 3 April 2014
Objectives: The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in
the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly
transmissible virus. Prior to the pandemic, many countries stockpiled NAIs and developed pandemic plans for
the use of antiviral drugs, based on either treatment of high-risk individuals and/or prophylaxis of contacts.
However, to date there has been a lack of in vivo models to test the efficacy of treatment or prophylaxis with
NAIs, for influenza-infected individuals or exposed contacts, in a household setting.
Methods: A ferret model of household contact was developed to study the efficacy of different prophylaxis regi-
mens in preventing infection in contact ferrets exposed to influenza A(H1N1)pdm09-infected index ferrets.
Results: Among the different prophylactic regimens, contact ferrets receiving oseltamivir prophylaxis twice daily
showed better outcomes than those receiving oseltamivir once daily. Benefits included a significant delay in the
time to secondary infection, lower weight loss and higher activity levels. The treatment of index ferrets at 36 h
post-infection did not influence either secondary infection rates or clinical symptoms in exposed contact ferrets.
Neither prophylaxis nor treatment prevented infection or reduced the duration of viral shedding, although clinical
symptoms did improve in infected animals receiving prophylaxis.
Conclusions: Different oseltamivir prophylaxis regimens did not prevent infections, but consistently resulted in a
reduction in symptoms in infected ferrets. However, oseltamivir prophylaxis failed to reduce viral titres, which
warrants further investigation in humans.
Keywords: antiviral, pandemic, A(H1N1)pdm09, neuraminidase inhibitors
Introduction
The prophylactic and/or therapeutic management of seasonal
influenza currently relies solely on the neuraminidase (NA) inhibi-
tors (NAIs) due to resistance of circulating influenza A viruses to
the older adamantane class of antivirals.1,2 The most widely pre-
scribed NAI is oseltamivir (TamifluTM), followed by zanamivir
(RelenzaTM), although other new NAIs, such as laninamivir and
peramivir, have recently been approved for use in Japan, South
Korea and China.3,4 Many countries have stockpiled antiviral
drugs, particularly oseltamivir, in preparedness for a future influ-
enza pandemic. For seasonal influenza, pre-exposure prophylaxis
with NAIs has been shown to be effective in preventing the devel-
opment of symptomatic infection in household contacts.5,6
Likewise, post-exposure prophylaxis with NAIs has also been
effective in reducing the spread of infection in household contacts
and communities.7,8 The emergence of the pandemic A(H1N1)
pdm09 influenza virus in March–April 2009 resulted in a signifi-
cant increase in the global use of NAIs for the treatment and
prevention of infection.9 Early NAI treatment of infected
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individuals or patients displaying influenza-like symptoms was
associated with reductions in both severe clinical outcomes and
mortality during the 2009 pandemic.10 In addition, post-exposure
oseltamivir prophylaxis was effective in reducing the rate
of A(H1N1)pdm09 viral infections in households11 and closed
institutional settings such as military camps.12 However, the
therapeutic and prophylactic effectiveness of oseltamivir against
mild seasonal influenza infections has been questioned following
a meta-analysis of clinical trial data.13
Prior to the 2009 pandemic, countries proposed different strat-
egies for the use of antivirals. Australia’s pandemic plan re-
commended liberal antiviral distribution for prophylaxis to limit
the spread of infection and buy time for vaccine development,14
but other countries, such as the USA, focused on the use of NAIs
for case treatment.15 The development of guidelines on the appro-
priate use of NAIs relies on antiviral effectiveness data derived
largely from field epidemiological studies or clinical studies.
However, these data may be limited or not available for newly
emerged strains, which could differ in virulence and transmissibility
from seasonal influenza viruses. Animal studies of NAI ef-
fectiveness, which have the advantage of being more rapidly estab-
lished than human studies, have the potential to provide early data
on the effectiveness of an NAI against a newly emerged influenza
virus. Consequently, an in vivo model to test the effectiveness of dif-
ferent antiviral treatment or prophylaxis regimens on influenza
infection and transmission in a household setting is needed.
Ferrets are the preferred animal model to assess influenza virus
infection, virulence and transmission as they display similar clin-
ical symptoms, pathogenesis and antibody responses to those
of humans16 and can be readily infected with seasonal, pandemic
or potentially pandemic influenza viruses such as A(H1N1)pdm09,
H7N9 and H5N1.17 – 21 In this study, we aimed to establish a
household contact model in ferrets to study the effectiveness of
different oseltamivir treatment and prophylaxis regimens in pre-
venting A(H1N1)pdm09 influenza virus infection.
Methods
Ethics statement
Ferrets were used with the approval of the CSIRO Australian Animal Health
Laboratory (AAHL) Animal Ethics Committee, in accordance with the
Australian Government, National Health and Medical Research Council
Australian code of practice for the care and use of animals for scientific pur-
poses (8th edition). The project license numbers are AEC 1340 and 1390.
Ferrets
Male and female ferrets weighing 1200–1900 g were used. Serum sam-
ples from ferrets were tested by the haemagglutination inhibition (HI)
assay against the reference strains A/California/7/2009 A(H1N1)pdm09,
A/Perth/16/2009 A(H3N2), B/Brisbane/60/2008 (B/Yamagata lineage)
and B/Brisbane/33/2008 (B/Victoria lineage) to ensure seronegativity
(titre ,20) against currently circulating influenza types/subtypes. Experi
-ments using ferrets were conducted in the BSL3 containment facilities at
the CSIRO AAHL.
Virus infection and oseltamivir treatment of ferrets
Index ferrets were either artificially infected (AI) by intranasal inoculation
with 1×106 TCID50 (median tissue culture infectious dose) of egg-grown
A/California/7/2009 A(H1N1)pdm09 (2.67×106 TCID50) or naturally in-
fected (NI) by exposure to AI donor ferrets for 48 h. A/California/7/2009
(passage E4) was kindly provided by CDC, Atlanta, USA, and was passaged
a further four times in embryonated hens eggs (passage E8) before being
used. The virus did not contain the D222G/E/N mutation or any other
haemagglutinin mutations known to be associated with receptor binding
or virulence. A 5 mg/kg dose of oseltamivir phosphate in ferrets is consid-
ered to be equivalent to the standard human adult dose of 75 mg, which is
normally delivered either once daily for prophylaxis or twice daily for treat-
ment.22 Oseltamivir phosphate (kindly provided by Hoffmann-La Roche
Ltd, Basel, Switzerland) was prepared at a concentration of 10 mg/mL in
a sterile 0.5% sugar/PBS solution and 5 mg/kg was delivered orally to con-
scious ferrets either once or twice daily with volume adjusted based on
weight (e.g. a 1200 g ferret received 600 mL). For pre-exposure prophylaxis,
contact ferrets were administered oseltamivir (either once or twice daily)
24 h prior to co-housing with an untreated NI index ferret (Figure 1a). For
post-exposure prophylaxis, contact ferrets were administered oseltamivir
(either once or twice daily) 24 h after co-housing with an untreated NI
index ferret (Figure 1b). To assess the effect of time between exposure
and the beginning of post-exposure prophylaxis, contact ferrets were
administered oseltamivir twice daily 12 h after co-housing with an AI
index ferret (Figure 1c). To compare the effect of contact prophylaxis
with index treatment, index ferrets were treated with oseltamivir twice
daily 36 h post-infection (12 h after being co-housed with untreated con-
tact ferrets) (Figure 1d). All oseltamivir treatment and prophylaxis regi-
mens were carried out for a total of 10 days. Seven ferrets (one donor
and six recipients) were housed in an open cage measuring 2 m by 1 m.
There was no direct airflow within the cage.
Ferret monitoring, measurement and sample collection
Body temperature, weight, activity score and nasal washes of all ferrets
were collected daily after the index ferrets were co-housed with contact
ferrets. Temperatures were measured daily using implanted temperature
transponders fitted to identification chips (LifeChip Bio-Thermow, Digivet,
Australia). Ferret activity score was assessed in a blinded manner daily
at the same time each morning by the same animal technician, who
was not aware of treatment group. A seven-level arbitrary activity score
system was used: 0, alert and fully playful; 0.5, alert but slightly less playful
than usual; 1, alert and playful when encouraged to play; 1.5, alert and
slightly playful when encouraged to play; 2, alert and slightly playful
with strong encouragement; 2.5, alert but not playful; 3, euthanized.
Activity score data are presented as the relative score compared with
the activity of the group receiving no intervention. Therefore, relative activ-
ity scores of .0 indicate increased activity compared with no intervention,
whereas relative activity scores of ,0 indicate decreased activity com-
pared with no intervention. Nasal washes were collected daily from
sedated ferrets (5 mg/kg xylazine) by instilling 1 mL of sterile PBS [supple-
mented with 1% (w/v) BSA, 100 mg/mL streptomycin and 100 U/mL peni-
cillin] into one nostril and allowing the liquid to flow out of the other nostril
into a collection tube. Nasal washes were stored at 2808C prior to analysis.
Blood samples were collected 10 days post-infection.
Virological, serological and NAI susceptibility analysis
Titres of infectious virus in the nasal washes were quantified by viral infect-
ivity assay and the TCID50 was determined.
23 Briefly, samples were serially
diluted 10-fold in PBS and each dilution was added in quadruplicate to flat-
bottom 96-well plates containing a confluent monolayer of MDCK cells.
Infected cells were incubated for 5 days at 378C, 5% CO2, followed by
assessment of cytopathic effect. Virus titres were calculated as described
by Reed and Muench.24 The influenza-specific antibodies in sera were
assessed with the HI assay.25 Briefly, sera treated with receptor-destroying
enzyme (RDE; Denka Seiken, Japan) were serially 2-fold diluted from a
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Figure 1. Experimental outline of the treatment and prophylaxis regimens used. (a) Pre- and (b) post-exposure prophylaxis of contact ferrets (C; blue)
24 h prior to or 24 h after A(H1N1)pdm09 exposure to NI index ferrets (green) in a co-housed environment. NI ferrets were infected by co-housing with AI
index ferrets (red) for 48 h. Experiments in (a) and (b) were carried out once. (c) Post-exposure prophylaxis of contact ferrets following 12 h of exposure to
AI ferrets. (d) Treatment of AI ferrets after 36 h post-infection (p.i.) with A(H1N1)pdm09. Experiments in (c) and (d) were carried out twice. SID, 5 mg/kg
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starting dilution of 1:20 in V-bottom 96-well plates. Virus (8 haemag-
glutination units) was added to all wells and 0.5% chicken red blood
cells were added after 1 h of incubation at room temperature. Positive
wells were defined as those where there was complete inhibition of haem-
agglutination. Known positive and negative sera were included as controls.
The NAI susceptibility of viruses cultured in MDCK cells was tested in a
fluorescence-based NA enzyme inhibition assay26 utilizing the substrate
MUNANA (Sigma-Aldrich, USA) at a final concentration of 0.1 mM to
yield an IC50 value.
RNA extraction, RT–PCR and pyrosequencing
Viral RNA was extracted from the ferrets’ nasal washes using the QIAamp
Viral RNA Mini Kit (Qiagen, CA, USA) and RT–PCR was performed using the
Superscript III One Step RT–PCR kit (Invitrogen) according to the manufac-
turer’s protocols. Pyrosequencing was carried out to detect the H275Y muta-
tion in the NA gene as described in Deng et al.27 Briefly, pyrosequencing
reactions were performed on a PyroMark ID (Qiagen) with PyroMark Gold
reagents (Qiagen) and results were analysed using PyroMark ID 1.0 software
to estimate the percentages of H275Y mutant and wild-type viruses by cal-
culating the ratio of the two peaks representing the wild-type and mutant.
Statistical analyses
A log-rank (Mantel–Cox) test and log-rank test for trend was used to com-
pare Kaplan–Meier curves reporting time to detect infection (detectable
viral titre in nasal wash). The two-tailed unpaired t-test was used to com-
pare day-by-day differences in percentage weight loss, body temperature,
activity score, virus titre and influenza-specific HI antibody (log scale)
among the different groups. A one-way ANOVA with Holm–Sidak’s mul-
tiple comparison test was used to test for differences in mean peak viral
load and mean day of peak viral load among the groups. A P value of
,0.05 was considered statistically significant.
Results
Ferret model of household contact
In the ferret model of household contact, index ferrets were either
AI by intranasal inoculation of influenza A(H1N1)pdm09 virus or
NI by exposure to AI donor ferrets for 48 h, prior to co-housing
with contact ferrets. NI index ferrets were used in the experiments
outlined in Figure 1(a and b) to represent natural transmission
to contact ferrets that were undergoing oseltamivir prophylaxis.
However, for experiments involving oseltamivir treatment
of index ferrets, AI ferrets were used to ensure the timing of
post-infection treatment of index ferrets was accurate (36 h)
(Figure 1d). To maintain consistency in the experiments outlined
in Figure 1(c and d), AI index ferrets were used for the no interven-
tion and 12 h post-exposure prophylaxis groups. The viral infec-
tions of untreated contact ferrets exposed to either an AI index
ferret or an NI index ferret were similar with respect to peak
viral load and duration of viral shedding, although the establish-
ment of infection was 1 day later in ferrets exposed to NI index
ferrets than in those exposed to AI index ferrets (Figure S1, avail-
able as Supplementary data at JAC Online).
Prophylaxis regimens: pre-exposure prophylaxis
of contact ferrets
To determine the efficacy of pre-exposure oseltamivir prophylaxis,
two groups of ferrets were orally administered oseltamivir either
once or twice daily starting 24 h prior to A(H1N1)pdm09 exposure
and continuing for 10 days after exposure (Figure 1a). The time for
all contact ferrets to become infected was significantly delayed in
the prophylaxis group dosed twice daily compared with the once-
daily prophylaxis and no intervention groups (twice-daily prophy-
laxis, day 10; once-daily prophylaxis, day 7; no intervention, day 6;
P¼0.043; Figure 2a). Virus shedding profiles of the single index
ferrets from each of the three groups were similar and therefore
are unlikely to have biased the infection of contact ferrets in the
different groups within this experiment (Figure S2A, available as
Supplementary data at JAC Online). Although twice-daily oselta-
mivir prophylaxis delayed the infection of contact ferrets, it did not
prevent all the contact ferrets becoming infected (Figure 2a).
However, percentage weight loss following infection among the
twice-daily oseltamivir prophylaxis group was significantly less
than in ferrets receiving either once-daily oseltamivir prophylaxis
or no intervention during days 1–4 post-exposure (Figure 2b). No
significant differences in body temperature were observed between
the three groups of contact ferrets (Figure 2c). Ferrets from once-
daily and twice-daily oseltamivir prophylaxis groups were signifi-
cantly more active than untreated ferrets on days 4, 5 and 9 and
days 4, 7, 8 and 9, respectively (Figure 2d). Despite these differences,
the contact ferrets in all three groups had similar HI antibody titres
and viral shedding patterns, with no significant difference in either
peak viral titres or duration of shedding (Figure 2e and f and Table 1).
Collectively, the data show that pre-exposure prophylaxis with two
doses of oseltamivir daily was effective in delaying infection of all
contact ferrets and improving clinical symptoms (reduced weight
loss and a higher activity score), whereas prophylaxis using only
one dose of oseltamivir daily appeared only to improve ferret
activity compared with no intervention (Table 2).
Prophylaxis regimens: post-exposure prophylaxis
of contact ferrets
To determine the efficacy of post-exposure oseltamivir prophy-
laxis, ferrets were co-housed with NI index ferrets for 24 h before
administering oseltamivir either once or twice daily for 10 days
(Figure 1b). Virus shedding profiles of the single index ferrets
from each of the three groups were again similar and therefore
are unlikely to have biased the infection of contact ferrets in the
different groups (Figure S2B, available as Supplementary data at
JAC Online). However, at the time when the index ferrets were
co-housed with contacts in this post-exposure prophylaxis experi-
ment, the viral titres of these index ferrets (4–5.5 log10 TCID50/
mL) were considerably greater than that of the index ferrets in
the pre-exposure prophylaxis experiment (0–1.75 log10 TCID50/
mL) (Figure S2A and B). As a result, it took only 2 days for
all untreated control ferrets in the post-exposure prophylaxis
experiment to become infected, compared with 6 days in the
pre-exposure prophylaxis experiment (Figures 2a and 3a). When
comparing within the 24 h post-exposure prophylaxis experiment,
neither dosing regimen (once- and twice-daily oseltamivir)
delayed the time of infection compared with untreated control
ferrets, with all becoming infected within 2 days of exposure
(Figure 3a). While the twice-daily post-exposure prophylaxis group
did show significantly less weight loss from day 4 to day 7 compared
with the control group, no significant effect on weight loss was seen
in the once-daily post-exposure prophylaxis group (Figure 3b). In
addition, the twice-daily post-exposure prophylaxis group also
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showed significantly less weight loss from day 3 to day 9 compared
with the once-daily post-exposure prophylaxis group (Figure 3b).
Neither of the post-exposure prophylaxis regimens (once- and
twice-daily oseltamivir) had an effect on body temperature
(Figure 3c). However, compared with the untreated ferrets, those
that received either once- or twice-daily oseltamivir in the post-
exposure prophylaxis groups were significantly more active across
much of the 10 day period (Figure 3d). Importantly, both post-
exposure prophylaxis regimens (once- and twice-daily oseltamivir)
did not alter viral shedding profiles or HI antibody titres (Figure 3e
and f and Table 1). Collectively, the data show that oseltamivir
administered either once or twice daily 24 h post-exposure
improved the activity of contact ferrets and reduced weight loss
(for twice-daily dosing only), but had no significant effect on infec-
tion, temperature, viral shedding kinetics or HI antibody response
(Table 2).
To determine the impact of reducing the time between ex-
posure and onset of oseltamivir prophylaxis, we compared
twice-daily oseltamivir prophylaxis of contact ferrets at 12 h post-
exposure with no intervention (Figure 1c). Virus shedding profiles
of the index ferrets in each group were similar, but as they were AI
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Figure 2. Clinical symptoms of contact ferrets receiving 24 h pre-exposure prophylaxis. (a) Proportion of uninfected contact ferrets (SID versus BID
versus no intervention, *P,0.05; log-rank test for trend in Kaplan–Meier curve). (b) Percentage weight loss. (c) Body temperature. (d) Activity score
of treated contact ferrets relative to ferrets with no intervention. (e) Virus titre in nasal washes. (f) Serum antibody titre. Contact ferrets, n¼6 in
each group. For (b), (c), (d) and (e), data are mean+SEM. SID 24 h pre-exposure versus no intervention, #P,0.05, ###P,0.001; BID 24 h
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improvement in ferret weighta
Significant difference
in body temperature
Days with significant improvement
in relative activity scoresb
Prophylaxis of contacts 24 h pre-exposure SID no day 2 no days 4, 5 and 9
BID yes days 1, 2, 3 and 4 no days 4, 7, 8 and 9
12 h post-exposure BID yes —c no days 3, 5, 7, 8 and 9
24 h post-exposure SID no —c no days 3, 4, 5, 6, 7 and 8
BID no days 4, 5, 6 and 7 no days 1, 4, 5, 6 and 8
Treatment of index 36 h post-infection BID no —c no days 3 and 4
SID, 5 mg/kg oseltamivir once daily; BID, 5 mg/kg oseltamivir twice daily.
aDays where the mean ferret weight loss was significantly less (P,0.05) than that of ferrets with no intervention.
bDays where the mean ferret relative activity score was significantly greater (P,0.05) than that of ferrets with no intervention.
cMean ferret weight loss was not significantly different from that of ferrets with no intervention.





24 h pre-exposure 24 h post-exposure 12 h post-exposure
no intervention
(n¼6) SID (n¼6) BID (n¼6)
no intervention
(n¼6) SID (n¼6) BID (n¼6)
no intervention
(n¼12) BID (n¼12)
Mean peak viral load
(log TCID50/mL)
a
4.90+0.29 4.25+0.22 5.17+0.23 5.46+0.51 4.25+0.28 4.83+0.50 4.81+0.16 4.90+0.34 4.65+0.27
Mean day of peak viral loadb 6.50+0.67 7.33+0.56 9.33+1.02 4.17+0.17 4.33+0.21 4.33+0.33 4.25+0.35 6.08+0.57* 4.83+0.32
SID, 5 mg/kg oseltamivir once daily; BID, 5 mg/kg oseltamivir twice daily.
*P,0.05, one-way ANOVA with Holm-Sidak’s multiple comparison test.
aMean peak viral load was calculated by averaging the maximum viral titres detected in contact ferrets.
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index ferrets (Figure S2A, B and C, available as Supplementary
data at JAC Online). Unlike 24 h post-exposure twice-daily oselta-
mivir prophylaxis, which did not delay the time of infection, 12 h
post-exposure twice-daily oseltamivir prophylaxis did significantly
delay infection compared with no intervention (time for all con-
tact ferrets to become infected: twice-daily oseltamivir, day 6;
no intervention, day 3; P¼0.03; Figure 4a). However, no significant
effect on body weight or body temperature was observed
(Figure 4b and c). Twelve hours post-exposure, twice-daily oselta-
mivir prophylaxis significantly improved activity score on all but
2 days (Figure 4d). As a result of the delayed infection, the peak
viral load for contact ferrets receiving 12 h post-exposure twice-
daily oseltamivir prophylaxis was shifted to day 6 compared
with day 4 in untreated ferrets (Table 1), but, importantly, the
mean peak viral titre and the duration of viral shedding were
not reduced as a result of oseltamivir prophylaxis (Table 1 and
Figure 4e). No significant differences in HI antibody titres were
observed (Figure 4f).
Treatment regimen: treatment of index ferrets 36 h
post-infection
To evaluate the effect of oseltamivir treatment of index ferrets on
the infection and clinical signs of contact ferrets (which were not
given prophylaxis), we initiated treatment at 36 h post-infection
(estimated to be 12 h post-symptom onset), a time period
designed to mimic when humans may be seeking and starting
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Figure 3. Clinical symptoms of contact ferrets receiving 24 h post-exposure prophylaxis. (a) Proportion of uninfected contacts. (b) Percentage weight
loss. (c) Body temperature. (d) Relative activity score of treated contact ferrets compared with ferrets with no intervention. (e) Virus titre in nasal washes.
(f) Serum antibody titre. Contact ferrets, n¼6 in each group. For (b), (c), (d) and (e), data are mean+SEM. SID 24 h post-exposure versus no intervention,
#P,0.05, ##P,0.01, ###P,0.001; BID 24 h post-exposure versus no intervention, *P,0.05, **P,0.01, ***P,0.001; SID 24 h post-exposure versus no
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oseltamivir treatment of the index ferret did not slow the rate of
infection of the co-housed contact ferrets (time for all contact fer-
rets to become infected: twice-daily oseltamivir-treated index,
day 4; no intervention, day 3; P¼0.10; Figure 5a). Contact ferrets
exposed to the treated index ferret experienced weight loss,
temperature rises, duration of viral shedding, HI antibody titres
and mean peak viral titres similar to those of ferrets exposed
to an untreated index ferret (Figure 5b, c, e and f and Table 1),
but had increased activity on days 3 and 4 post-exposure only
(Figure 5d). A comparison of viral shedding in the oseltami-
vir-treated AI index ferrets (n¼2) compared with the untreated
AI index ferrets (n¼4) revealed no significant difference in
viral load or duration of shedding (Figure S3, available as
Supplementary data at JAC Online).
H275Y NA mutation in one infected index ferret following
oseltamivir treatment
To determine whether oseltamivir treatment or prophylaxis leads
to the emergence of oseltamivir-resistant variants, we isolated
viruses from nasal washes of both index and contact ferrets in
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Time post-exposure (days) Time post-exposure (days)
*
No intervention
Contact BID 12 h post-exposure
No intervention
Contact BID 12 h post-exposure
No intervention
Contact BID 12 h post-exposure
Contact BID 12 h post-exposure
No intervention
Contact BID 12 h post-exposure
No intervention
Contact BID 12 h post-exposure
6 8 10
Figure 4. Clinical symptoms of contact ferrets receiving 12 h post-exposure prophylaxis. (a) Proportion of uninfected contacts [*P,0.05, log-rank test
(Mantel–Cox) on Kaplan–Meier curve]. (b) Percentage weight loss. (c) Body temperature. (d) Relative activity score of treated contact ferrets compared
with ferrets with no intervention. (e) Virus titre in nasal washes. (f) Serum antibody titre. Contact ferrets, n¼12 in each group. For (b), (c) and (d), data are
mean+SEM of all individual ferrets from two independent experiments. Contact BID 12 h post-exposure versus no intervention, *P,0.05, ***P,0.001;
two-tailed unpaired t-test. BID, 5 mg/kg oseltamivir twice daily.
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inhibition assay to measure oseltamivir susceptibility. The mean
concentration of oseltamivir required to inhibit NA activity by
50% (IC50) (+ SD) for all virus isolates was 0.3+0.2 nM, with
none displaying either reduced (IC50 .10-fold above the mean)
or highly reduced (IC50 .100-fold above the mean) inhibition.
However, because the NA inhibition assay is unable to detect
low proportions of resistant virus in a mixed viral population,
RNA from all nasal washes was tested in a pyrosequencing
assay for the detection of the H275Y NA mutation, known to con-
fer resistance to oseltamivir in A(H1N1)pdm09 viruses. A sample
from one of the oseltamivir-treated index ferrets on day 5 post-
infection contained a mixed population of resistant and suscep-
tible viruses, with 17% of viruses containing the H275Y NA
mutation and 83% the susceptible wild-type virus. The H275Y
variant was not detected in any of the nasal washes of co-housed
contact ferrets, presumably because they had become infected
before the selection of resistant virus in the index ferret.
Discussion
Here we show that, using our ferret model, oseltamivir treatment
of an index case had minimal or no impact on transmission to sec-
ondary contacts, whereas pre-exposure prophylaxis of contacts
resulted in delayed infection and improved clinical symptoms in
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Index treated BID 36 h p.i.
No intervention
Index treated BID 36 h p.i.
6 8 10
No intervention
Index treated BID 36 h p.i.
No intervention
Index treated BID 36 h p.i.
Figure 5. Clinical symptoms of untreated contact ferrets co-housed with oseltamivir-treated index ferrets 36 h post-infection (p.i.). (a) Proportion of
uninfected contacts. (b) Percentage weight loss. (c) Body temperature. (d) Relative activity score of treated contact ferrets compared with ferrets
with no intervention. (e) Virus titre in nasal washes. (f) Serum antibody titre. Contact ferrets, n¼12 in each group. For (b), (c) and (d), data are
mean+SEM of all individual ferrets from two independent experiments. BID index 36 h p.i. versus no intervention: #P,0.05; two-tailed unpaired









niversity of Adelaide user on 18 O
ctober 2019
delivered twice daily rather than once daily. Twice-daily oseltami-
vir prophylaxis at 12 h post-exposure was effective in delaying
infection and improving clinical symptoms, but delaying prophy-
laxis until 24 h post-exposure resulted in the loss of most of
these benefits. However, even at 24 h post-exposure, both dosing
regimens (once- and twice-daily) appeared to improve ferret
activity significantly compared with untreated control ferrets.
Treatment for human influenza is recommended within 48 h of
symptom onset, with delays resulting in reduced effectiveness in
the treated patient.28 However, little is known about how the tim-
ing of index treatment may alter the transmission of influenza to
exposed contacts. In our study, we treated index ferrets at 36 h
post-infection, which was estimated to be 12 –24 h after
symptom onset, but this intervention had little or no effect on
the infection of contact ferrets. This demonstrated that, in our
model, prophylaxis of contacts was necessary to alter normal
transmission. Numerous human studies have shown that antiviral
prophylaxis has high protective efficacy against influenza infec-
tions.5,7,8,29,30 In a proof-of-concept study involving 33 subjects,
prophylaxis with 100 mg of oseltamivir once or twice daily for
5 days, starting 26 h prior to intranasal challenge with A/Texas/
36/91 (H1N1), significantly reduced infection rates and inhibited
viral shedding compared with placebo.29 A follow-up multicentre
clinical study by Hayden et al.5 demonstrated a similar protective
effect of pre-exposure prophylaxis against seasonal influenza
infections in healthy, non-immunized subjects who received
either once-daily (75 mg/kg) or twice-daily (150 mg/kg) prophy-
laxis with oseltamivir. Likewise, post-exposure prophylaxis of con-
tacts in a randomized controlled trial also showed high protective
efficacy in individuals and contacts.7,8
Compared with the benefits of pre- or post-exposure oseltami-
vir prophylaxis observed in the human studies, the effects of osel-
tamivir intervention described in our ferret model were more
modest. This could be a result of study limitations, such as the dif-
ferences in viral titres of donor ferrets between pre- and post-
exposure prophylaxis experiments, which could have biased the
speed at which contact ferrets became infected. Other limitations
of the study include the use of only a twice-daily, and not also
once-daily, oseltamivir dosing regimen in the 12 h post-exposure
prophylaxis experiment. In addition, the prolonged co-housing
of index and contact ferrets in very close proximity meant that
the duration and magnitude of virus exposure experienced by
contact ferrets were likely to be considerably higher than those
in a typical human household context. In addition, as contacts
became infected, they became additional index ferrets, thereby
increasing the probability of infecting further contact animals.
Both factors, together with the observation that ferrets can trans-
mit A(H1N1)pdm09 virus during both the early and late periods of
infection,31 may explain why none of the oseltamivir interventions
was able to prevent infection.
To more closely mimic the average contact parameters
observed in a typical household context, future studies using
this ferret model should consider modifications such as housing
ferrets in separate but closely located cages to allow only aerosol
or droplet transmission and/or artificially manipulating the dur-
ation of exposure between index and contact ferrets. Separation
of human index cases from exposed contacts receiving prophy-
laxis has been shown in a military setting to dramatically reduce
the rate of A(H1N1)pdm09 infection.12 Additionally, ferrets with
pre-existing immunity to a distantly related influenza virus rather
than influenza-naive ferrets, as used in our study, may better
represent a typical human adult who has been previously infected
or vaccinated with influenza. Finally, while the treatment dose of
5 mg/kg twice daily with oseltamivir in ferrets has been widely
accepted as the equivalent dose to that used in the treatment
of human influenza infections (75 mg/kg twice daily)4,32 and is
widely used in many ferret studies,20,22,33,34 further detailed phar-
macokinetic and pharmacodynamic studies in ferrets are needed
to allow a robust comparison with equivalent human data.35,36
Although pre- or post-exposure oseltamivir prophylaxis of con-
tact ferrets was unable to prevent A(H1N1)pdm09 infection or sig-
nificantly reduce viral shedding, it did appear to reduce weight loss
and improve activity, a similar finding to that reported by
Govorkova et al.37 for the treatment of index ferrets at 2 or 24 h
post-infection. The reason for the improved clinical signs in the
absence of clear virological improvement remains unclear,
although a recent report by Maines et al.38 on the effect of local
innate immune responses to virus infection may provide an
explanation. Among parameters not measured in our study are
the levels of proinflammatory mediators in the respiratory tract,
including IFNa/b, TNFa, IL-6, IL-12, CXCL9 and CXCL11, which
have been shown to correlate with viral transmission, clinical
signs of infections and influenza virus shedding in the ferret
model.38 In mice, the proinflammatory cytokine IL-6 has also
been demonstrated to play an important role in governing
antiviral immunity by limiting inflammation and promoting anti-
viral T cell responses to lung injury.39 In humans infected with
A/Texas/36/91 (H1N1), oseltamivir treatment was associated
with significantly lower levels of proinflammatory cytokines,
such as IFNg, TNFa and IL-6, in nasal lavage fluid.29 Therefore,
oseltamivir prophylaxis in the ferrets may result in down-
regulation of various proinflammatory mediators, resulting in alle-
viation of clinical symptoms.
The findings of our study provide the first step in establishing
an in vivo model that will help to determine the most effective
way to use antiviral drugs against influenza in a household trans-
mission setting. We showed that, under most of the prophylaxis
regimens, the administration of oseltamivir significantly improved
activity, but had little or no effect on viral shedding. In many
human oseltamivir clinical trials, swabs have been taken only
from symptomatic patients29,40,41 as opposed to our ferret
model, where all ferrets were swabbed daily regardless of symp-
toms. However, studies have shown that, following oseltamivir
treatment, asymptomatic patients do shed influenza virus.8,11
This suggests that our finding that ferrets displayed improved
activity while still shedding high titres of virus may extend to
the human situation.8,11 From a public health perspective, it
would be concerning if patients who received oseltamivir prophy-
laxis or treatment were returning to normal social activities pre-
maturely due to experiencing mild or no symptoms while still
shedding virus. These findings caution against over-reliance on
pharmaceutical measures to reduce influenza transmission, and
reinforce the importance of developing robust evidence-based
guidelines for adjunct personal hygiene and social distancing
measures to limit the spread of disease.
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